JOP20230276A1 - تركيبات وطرق لعلاج الاكتئاب - Google Patents

تركيبات وطرق لعلاج الاكتئاب

Info

Publication number
JOP20230276A1
JOP20230276A1 JOJO/P/2023/0276A JOP20230276A JOP20230276A1 JO P20230276 A1 JOP20230276 A1 JO P20230276A1 JO P20230276 A JOP20230276 A JO P20230276A JO P20230276 A1 JOP20230276 A1 JO P20230276A1
Authority
JO
Jordan
Prior art keywords
patient
atecaprant
reuptake inhibitor
formulas
methods
Prior art date
Application number
JOJO/P/2023/0276A
Other languages
Arabic (ar)
English (en)
Inventor
Vanina Popova
Darrel Pemberton
Srihari Gopal
Wayne C Drevets
Adam Savitz
Mark Schmidt
Iva Kezic
Chakradhar Lagishetty
Rama Melkote
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/307,858 external-priority patent/US11266627B1/en
Priority claimed from US17/670,123 external-priority patent/US12161622B2/en
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of JOP20230276A1 publication Critical patent/JOP20230276A1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)
JOJO/P/2023/0276A 2021-05-04 2023-11-02 تركيبات وطرق لعلاج الاكتئاب JOP20230276A1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17/307,858 US11266627B1 (en) 2021-05-04 2021-05-04 Compositions and methods for the treatment of depression
US17/670,123 US12161622B2 (en) 2021-05-04 2022-02-11 Compositions and methods for the treatment of depression
US202263313792P 2022-02-25 2022-02-25
PCT/IB2022/054085 WO2022234457A1 (en) 2021-05-04 2022-05-03 Compositions and methods for the treatment of depression

Publications (1)

Publication Number Publication Date
JOP20230276A1 true JOP20230276A1 (ar) 2023-11-02

Family

ID=81654924

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0276A JOP20230276A1 (ar) 2021-05-04 2023-11-02 تركيبات وطرق لعلاج الاكتئاب

Country Status (16)

Country Link
EP (1) EP4333835A1 (https=)
JP (1) JP2024516297A (https=)
KR (1) KR20240004857A (https=)
AU (1) AU2022268720A1 (https=)
BR (1) BR112023023030A2 (https=)
CA (1) CA3219079A1 (https=)
CL (1) CL2023003259A1 (https=)
CO (1) CO2023015571A2 (https=)
IL (1) IL308221A (https=)
JO (1) JOP20230276A1 (https=)
MX (1) MX2023013040A (https=)
PE (1) PE20241784A1 (https=)
PH (1) PH12023552963A1 (https=)
TW (1) TW202313003A (https=)
UY (1) UY39754A (https=)
WO (1) WO2022234457A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AU2023231493A1 (en) * 2022-03-07 2024-10-24 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
WO2024216046A1 (en) * 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating anhedonia
WO2024216061A1 (en) * 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating depression and anhedonia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5345637B2 (ja) 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト

Also Published As

Publication number Publication date
CO2023015571A2 (es) 2023-11-30
EP4333835A1 (en) 2024-03-13
IL308221A (en) 2024-01-01
CL2023003259A1 (es) 2024-05-31
WO2022234457A1 (en) 2022-11-10
PH12023552963A1 (en) 2024-03-11
PE20241784A1 (es) 2024-09-06
MX2023013040A (es) 2024-01-05
UY39754A (es) 2022-11-30
JP2024516297A (ja) 2024-04-12
KR20240004857A (ko) 2024-01-11
AU2022268720A1 (en) 2023-12-21
TW202313003A (zh) 2023-04-01
BR112023023030A2 (pt) 2024-02-15
CA3219079A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
JOP20230276A1 (ar) تركيبات وطرق لعلاج الاكتئاب
MX2024010140A (es) Nuevos metodos.
CY1122698T1 (el) Ελιγλουστατη (genz 112638) ως αναστολεας της συνθετασης γλυκοζυλοκεραμιδιου για χρηση σε μια μεθοδο θεραπευτικης αγωγης της νοσου fabry ή gaucher, με τη μεθοδο να περιλαμβανει την προσαρμογη της ατομικης θεραπευτικης δοσης στον ρ-450 μεταβολισμο του ασθενους
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
EA202091597A1 (ru) Способы и композиции для лечения апноэ сна
ATE506059T1 (de) Therapie zur behandlung der überaktiven blase
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EA201270041A1 (ru) Лечение рассеянного склероза лаквинимодом
MX2021006985A (es) Metodos para el tratamiento de la depresión.
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
Şahin et al. Duloxetine-induced sleep bruxism in fibromyalgia successfully treated with amitriptyline.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
BR112022010733A2 (pt) Métodos para tratar dor
MX2022012001A (es) Tratamiento preventivo de la migra?a.
EA202193276A1 (ru) Способы лечения холангиокарциномы
AR045423A1 (es) Combinaciones de analiticos y antidepresivos
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
MX2024008618A (es) Composiciones y métodos para el tratamiento de la depresión.
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
BR112022001814A2 (pt) Métodos de tratamento de câncer multifocal
BR112023004354A2 (pt) Compostos derivados de sulfamato para uso no tratamento ou alívio de um transtorno psiquiátrico